Company news

Biofrontera Inc. news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

Biofrontera Inc. Names Gerard DiGirolamo as National Sales Director

September 12, 2022

Biofrontera Inc. Announces Notice of Allowance for Nanoemulsion Composition-of-Matter U.S. Patent

September 5, 2022

Biofrontera Inc.’s Leslie Hopkins Named PM360 Trailblazer 2022 Brand Champion for Dermatology

August 17, 2022

Biofrontera Inc. Reports Second Quarter 2022 Financial Results and Provides a Business Update

August 11, 2022

Biofrontera Inc. to Report Second Quarter Financial Results on August 12, 2022

August 3, 2022

Biofrontera Inc. Announces Patent in Australia for Novel Illumination Protocols Granted to Biofrontera Bioscience GmbH

July 31, 2022

Biofrontera Inc. Announces Exercise of Existing Warrants and Issuance of Warrants in Private Placement

July 26, 2022

Biofrontera Inc. Announces Preliminary Product Revenues for the Second Quarter of 2022

July 11, 2022

Biofrontera Inc. Announces Closing of $9.4 Million Private Placement

May 18, 2022

Biofrontera Inc. Announces Pricing of $9.4 Million Private Placement

May 15, 2022

Biofrontera Inc. Reports First Quarter 2022 Financial Results and Provides a Business Update

May 12, 2022

Biofrontera Inc. to Report First Quarter Financial Results on May 13, 2022

May 5, 2022

Biofrontera Inc. to Showcase Actinic Keratosis Treatments at the Music City Symposium for Cosmetic Advances & Laser Education

May 4, 2022

Biofrontera Launches New Patient-Focused Websites for Ameluz® and Xepi®

April 20, 2022

Biofrontera Inc. Announces FDA Approval of Biofrontera Pharma GmbH as a Contract Laboratory for Ameluz®

April 12, 2022

Biofrontera Inc. Reports Fourth Quarter and Full Year 2021 Financial Results and Provides a Business Update

April 7, 2022

Biofrontera Inc. Announces Preliminary Product Revenues for the First Quarter of 2022

April 5, 2022

Biofrontera Inc. to Report Fourth Quarter and Full Year 2021 Financial Results on April 8, 2022

March 31, 2022

Biofrontera to Showcase Actinic Keratoses and Impetigo Treatments at the 2022 American Academy of Dermatology Annual Meeting

March 16, 2022

Biofrontera Inc. Announces FDA Orange Book Listing of U.S. Patent for BF-RhodoLED® XL, Extends Protection of Ameluz®-PDT Through October 2040

March 13, 2022

Biofrontera Inc. Appoints Kevin D. Weber to its Board of Directors

March 6, 2022

Biofrontera Inc. provides Update on Patient Recruitment for Phase III Study for the Treatment of sBCC with Ameluz®-PDT

January 31, 2022

Biofrontera Inc. Announces Preliminary Revenue for the Fourth Quarter and Full Year 2021

January 12, 2022

Biofrontera Inc. Announces Participation in Two Dermatology Conferences in January

January 9, 2022

Biofrontera Inc. announces reduction of Biofrontera AG shareholding to less than 50% through warrant exercises

December 29, 2021

Biofrontera Inc. Announces Enrollment of First Subject in Phase 2b Clinical Trial Evaluating Ameluz® + BF-RhodoLED® in Moderate-to-Severe Acne

December 12, 2021

Biofrontera Inc. Announces Notice of Allowance for U.S. Method-of-Use Patent on PDT-lamp

December 7, 2021

Biofrontera Inc. Enrolls First Subject in Phase 1 Safety Study Evaluating Photodynamic Therapy with Three Tubes of Ameluz®

December 5, 2021

Biofrontera Inc. Announces Notice of Allowance for U.S. Patent on Innovative Illumination Protocol

December 1, 2021

Biofrontera Inc. Announces Closing of $15 Million Private Placement

November 30, 2021

Biofrontera Inc. Reports Third Quarter 2021 Financial Results and Provides Business Update

November 29, 2021

Biofrontera Inc. Pricing of $15 Million Private Placement Priced At-the-Market Under Nasdaq Rules

November 28, 2021

Biofrontera Inc. to Report Third Quarter Financial Results on November 30, 2021

November 22, 2021

Biofrontera Kicks Off US Clinical Study Program for Ameluz®

November 15, 2021

Biofrontera Inc. Announces Closing of Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Warrants

November 1, 2021

Biofrontera Inc. Announces Pricing of $18.0 Million Initial Public Offering

October 27, 2021

← Newer news releases

Calls

The 5 newest of 20 calls. Every call is listed under its year.